Standalone and Consolidated Financial results for the period ended on 31st March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported strong FY25 results with revenue from operations rising about 30% to ₹45,170.62 lakhs (vs ₹34,657.69 lakhs in FY24) and net profit growing roughly 33% to ₹2,080.76 lakhs (vs ₹1,562.34 lakhs). Total income stood at ₹45,626.83 lakhs and EPS rose to ₹44.83 from ₹33.66. The Board recommended a final dividend of 7% (₹0.70 per share on ₹10 face value) subject to shareholder approval. Consolidated net profit was ₹1,973.93 lakhs. The auditor issued an unmodified (clean) opinion on both standalone and consolidated results. However, operating cash flow was sharply negative at ₹(2,888.33) lakhs versus ₹(43.87) lakhs last year, and the auditor flagged delays in transferring unclaimed dividends and shares to the IEPF for FY15-16 and FY16-17.
Positive top-line and profit growth along with a dividend declaration are supportive for shareholders, but the steeply negative operating cash flow, rising trade receivables (~₹17,712 lakhs, nearly 2.7x last year), and higher short-term borrowings (~₹15,679 lakhs, up 69%) signal working-capital stress that investors should watch closely.